ESMO Open

Papers
(The H4-Index of ESMO Open is 47. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
OP01-2 Changes in the tumor microenvironment in recurrent head and neck squamous cell carcinoma and its implication on efficacy of immune checkpoint inhibitors216
PP289 Potential anti-tumour therapy in nasopharyngeal carcinoma: MDM2 siRNA-based approaches202
PP075 Xia Yuxue decoction inhibits hepatocellular carcinoma metastasis by reducing the abundance of the tumor-resident bacterium Brachybacterium sp.171
PP002 Unravelling the effects of bisphenol A on colorectal cancer progression in obese Sprague-Dawley rats154
PP153 A randomized, open-label phase ii study comparing a novel regimen of dose-dense docetaxel-cyclophosphamide alternating with epirubicin-cisplatin against anthracycline-taxane in early TNBC, strat154
PP175 Unexpected high frequency of pathogenic germline variant (rs34804482, NM_018490.3: c.2531A>G) of the LGR4 gene in Tuvan ethnic group from West Siberia134
35P Genomic and clinical landscape of metastatic hormone receptor-positive breast cancers carrying ESR1 alterations122
140P Use of chemotherapy and loco-regional therapy for stage IA triple-negative breast cancer and their association with oncologic outcomes: A cancer registry study122
130P Progesterone receptor (P) status and survival outcomes of ER-negative breast cancer: A population-based cohort study122
2O Prostate cancer BRCA mutation prediction using multiple-instance learning and histopathology120
137P PHANTOM: Bootstrap inference of single-cell tumour phylogenies by integrating sequencing read counts117
6P An innovative evidence-based laboratory medicine (EBLM) test to help doctors in the screening of ovarian cancer109
217P Switching cyclin-dependent kinase inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/human epidermal growth factor-negative (HER2-) advanced breast cancer (ABC) who experienced93
Table of Contents93
97P Drug sensitivity prediction based on RNA expression profiling in colorectal cancer organoids90
Table of Contents88
Table of Contents87
ESMO82
107P Clinicopathologic features of breast cancer patients in a single tertiary hospital in the Philippines74
258P Real-world (rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2-negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherap72
284P Risk assessment for systemic recurrence in HER2-low breast cancer: Evaluating hormone receptors and immunohistochemical profiles68
266O Safety of assisted reproductive techniques in young BRCA carriers with a pregnancy after breast cancer: Results from an international cohort study68
115P Impact of clinical and treatment factors on trabectedin toxicity in soft tissue sarcomas68
50P Combination of platinum-based chemotherapy with immunotherapy in treatment of extrapulmonary neuroendocrine carcinoma: A retrospective study66
76P Relative dose-intensity of trabectedin and outcome of advanced L-sarcomas66
143P Post-recurrence treatment in modern adjuvant or neoadjuvant soft-tissue sarcoma randomized trials: A cross-sectional study of published trials between 2015 and 202466
PP018 PAK1 inhibitor IPA-3 mitigates metastatic prostate cancer-induced bone remodeling65
232P Real-world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom64
Editorial Board64
68P Prognosis of ovarian cancer patients with the Mexican founder mutation (a BRCA1 long genomic rearrangement) compared with other BRCA1/2 mutations64
63P Redefining the role of CA 19-9 as a prognostic marker in epithelial ovarian cancer63
107P The actin cytoskeleton as a new target structure for metastasizing osteosarcoma63
57P Two cases of adult rhabdomyosarcoma of the head and neck successfully treated with pazopanib59
37P Dose transition pathways for time-to-event continual reassessment method (TITE-CRM): Will imposing a waiting time result in better performance?59
100P Combinatorial treatment strategies for overcoming the immunotherapy resistance in soft tissue sarcomas57
267P Ultrasound-guided injection with or without rehabilitation exercise in breast cancer survivors with subacromial-deltoid bursitis: Long-term results of a pilot randomized clinical study56
103P Impact of Prosigna test on treatment decision in lymph node-negative early breast cancer: A prospective multicenter study (EMIT1)56
174P Endocrine disruptors and life STILe in patients carrying BRCA pathogenic VAriants with breast and/or ovarian CAncer and women without neoplasm: The STILVARCA study54
118P Real-world treatment patterns and clinical outcomes among high risk, early stage HER2-negative breast cancer (BC) patients in Alberta, Canada54
142P The predictive value of progesterone receptor expression on pCR following neoadjuvant chemotherapy in breast cancer54
144P TRIple-negative breast cancer PrOspective registry in MiddLe East AfrIca (TRIPOLI) study: Interim analysis of treatment outcomes in patients who received neoadjuvant therapy53
148P Identification of potential predictive biomarkers for ovarian cancer chemotherapy response51
146P The prognosis value of heat-shock proteins in esophagogastric cancer: A systematic review and meta-analysis51
180P Improving the referral pathway for breast cancer patients: Lessons learnt from 1-year pilot51
70P Invasive lobular breast cancer (ILC), an overlooked subtype in clinical trials50
55P The SOS inhibitor BAY293 contributes to amplified vertical inhibition of the MAP kinase pathway in human melanoma cells49
Editorial Board48
51O The European Prospective Investigation into Cancer and nutrition cohort (EPIC): A gateway to rare cancer epidemiological research – Insights from the EPIC Rare Cancers Working Group47
0.10851001739502